REYON Pharmaceutical Co (102460) Fair Value & Analysis
Healthcare · KR · Market cap 182B KRW
Fair value as of: Jul 7, 2026
From 2 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 54,044 KRW to 8,047 KRW (−85.1%) since Jun 24, 2026. Share price +1.8% over the past month.
Price vs Fair Value (12 months)
12‑month range 9,780 KRW – 13,750 KRW · fair‑value band 6,005 KRW – 12,010 KRW · the 10,170 KRW price screens above the 8,047 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
REYON Pharmaceutical Co (102460) currently trades at 10,170 KRW, while our model-based Fair Value estimate is 8,047 KRW — implying the stock looks roughly 20.9% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, REYON Pharmaceutical Co generated revenue of 126B KRW at a net margin of 10.7%. Revenue declined 1.9% year over year. It earns a return on equity of 6.8%. Net debt stands at 208B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 6,005 KRW (bear case) to 12,010 KRW (bull case); at 10,170 KRW, the current price sits within that range. The share trades about 30% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -21%, 102460 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
REYON Pharmaceutical Co reported revenue of 146B KRW in FY2025 versus 143B KRW in FY2021, a compound +0.5%/yr. Reported net income was −29.6B KRW in FY2025.
Is 102460 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is REYON Pharmaceutical Co (102460) undervalued?
What is the fair value of 102460?
What is the quality score of 102460?
What is the revenue of REYON Pharmaceutical Co (102460)?
What is the net profit margin of 102460?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.